Studies on central nervous system depressants (13) "Structure activity relationship of some 3:4:5 trimethoxy benzamides".
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H L Sharma.
Explore the source record for details and available documents.
Adult (70 d) and neonatal (7 d) male rats were dosed (i.p.) with 37 MBq/kg (1 mCi/kg; approximately 1 microgram elemental indium/kg) 114mIn, a transferrin-binding radionuclide. In adults, approximately 0.25% of the injected activity localised within the testis by 48 h postinjection and remained constant for up to 63 d. In neonates, 0.06% of the activity was in the testis by 48 h, and this declined such that by 63 d only 0.03% remained. At 63 d, treated rats had reduced sperm head counts and abnormal testicular histology that was more marked in animals dosed as adults than as neonates. In vitro, uptake of 114mIn into seminiferous tubules isolated from 7-, 20-, or 70-d-old rats was compared with that of 125I. Both radionuclides were readily accumulated by the tubules. Whilst 114In uptake into 20- and 70-d tubules was inhibited by excess transferrin, uptake into 7-d tubules was unchanged. 125I uptake was not affected by excess transferrin. These data support the contention that some radionuclides may cross the blood-testis barrier by utilisation of the physiologic iron-transferrin pathway, which may lead to greater testicular damage in adult compared to neonatal animals.
Explore the source record for details and available documents.
"The objective of the present paper is to summarise trends in geographic mobility and expectancy in the U.S.A. between 1956-1987, using Current Population Survey (CPS) data and to determine the responsible factors that can affect mobility rates utilizing logistic regression based on 1979 and 1980 public use sample tapes data from the National Health Interview Survey.... Mobility rates reveal a general downward trend in the U.S.A.... Overall mobility rates remained rather constant at slightly less than 20 per cent from the mid fifties to the mid sixties. This has fallen steadily since 1970 to a relatively low current rate of about 17 per cent. This rate rose slightly from 1985 to 1987." (SUMMARY IN FRE AND ITA)
"Based on certain assumptions, a probability model for number of migrants has been proposed. The model involves several parameters. The estimates of some of the parameters are determined assuming that the rest are known." The model is applied to data from India taken from a 1978 survey of 3,514 households in villages classified as semi-urban, remote, or growth centers.
The author suggests some probability models for the distribution of number of boys in a family and assesses the suitability of these models using previously published data. "Also, the correlation coefficient between the number of boys and girls in a family for the same data has been determined in the case of each model."
This paper is a preliminary report of a clinical trial for the treatment of patients with refractory chronic lymphocytic leukaemia, using autologous In-114m-labelled lymphocytes. Fourteen patients have been treated so far with doses ranging from 69 to 211 MBq. All patients had progressive low grade NHL, resistant to chemotherapy and conventional radiotherapy. Following the intravenous administration of radiolabelled autologous lymphocytes 53% (range 33-92%) of the activity accumulated in the spleen, 35% (21-64%) in the liver and 5% in the bone marrow. The initial response in all patients was a rapid decrease in lymphocyte count in peripheral blood. 10 of the 14 (72%) patients showed a response to the treatment. In 2 patients, there was a complete response which lasted 24 and 36 months respectively, 8 patients showed a partial response of 2 to 17 months duration. None of the patients experienced any subjective toxicity although myelosuppression was seen in all patients. This is a novel concept for the administration of therapeutic radiation in a selective way for the treatment of lymphoid cell malignancy and has produced significant antitumour effect in patients with highly resistant disease. The trial is ongoing and a full report will be published on its completion.